Carboplatin Accord 10 mg/ml koncentrat till infusionsvätska

DRUG3 trials

Sponsors

Karolinska University Hospital, Kancera AB

Conditions

Non-metastatic HER2-positive Breast CancerRecurrent epithelial ovarianResectable locally advanced squamous cell carcinoma (SCC) of the esophagusfallopian tubeor primary peritoneal cancer.

Phase 1

KANDOVA - A two-part Phase Ib/IIa study to evaluate the safety and tolerability of KAND567, in combination with carboplatin therapy, and to determine the Recommended Phase II Dose (RPIID) of KAND567. An open-label, multicenter dose escalation study with an expansion cohort in women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.

CompletedCTIS2024-515572-13-00

Kancera ABfallopian tube, or primary peritoneal cancer., Recurrent epithelial ovarian

Start: 2023-04-26End: 2025-04-03Target: 30Updated: 2025-03-13

Phase 2

A Randomized Trial of Trastuzumab Deruxtecan and Biology-Driven Selection of Neoadjuvant Treatment for HER2-positive Breast Cancer: ARIADNE

RecruitingCTIS2022-501504-95-00

Karolinska University HospitalNon-metastatic HER2-positive Breast Cancer

Start: 2023-06-23Target: 402Updated: 2025-08-18

Phase 3

NEoadjuvant chemoradiotherapy for Esophageal squamous cell carcinoma versus Definitive chemoradiotherapy with salvage Surgery as needed (The NEEDS Trial)

RecruitingCTIS2022-500966-82-00

Karolinska University HospitalResectable locally advanced squamous cell carcinoma (SCC) of the esophagus

Start: 2020-03-11Target: 235Updated: 2025-05-07

Related Papers

Randomised trial of trastuzumab deruxtecan and biology-driven selection of neoadjuvant treatment for HER2-positive breast cancer: a study protocol of ARIADNE

BMJ Open2025-08-011 citations

Machine learning-based spatial characterization of tumor-immune microenvironment in the EORTC 10994/BIG 1-00 early breast cancer trial.

2025-03-073 citations